Oasmia Pharmaceutical AB Stock NORDIC GROWTH MARKET
Equities
OASM
SE0000722365
Pharmaceuticals
Sales 2022 | 3.04M 292K 398K | Sales 2023 | 6.61M 635K 866K | Capitalization | 219M 21.07M 28.72M |
---|---|---|---|---|---|
Net income 2022 | -357M -34.3M -46.76M | Net income 2023 | -129M -12.4M -16.9M | EV / Sales 2022 | 32.6 x |
Net cash position 2022 | 134M 12.91M 17.6M | Net cash position 2023 | 77.04M 7.4M 10.09M | EV / Sales 2023 | 21.5 x |
P/E ratio 2022 |
-0.6
x | P/E ratio 2023 |
-1.7
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 61.42% |
Latest transcript on Oasmia Pharmaceutical AB
Managers | Title | Age | Since |
---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 66 | 23-01-22 |
Robert Maiorana
DFI | Director of Finance/CFO | 64 | 20-11-30 |
Heidi Ramstad
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 44 | 19-03-18 | |
Hege Hellstrom
BRD | Director/Board Member | 59 | 19-09-25 |
Pål Ryfors
BRD | Director/Board Member | 41 | 22-05-24 |
1st Jan change | Capi. | |
---|---|---|
+42.60% | 739B | |
+32.34% | 598B | |
-5.74% | 353B | |
+17.79% | 318B | |
+3.37% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B |